- NetScientific said portfolio company ProAxsis had received positive early data from a major clinical trial funded by the British Lung Foundation and the European Respiratory Society.

'This encouraging data published in the renowned European Respiratory Journal demonstrates ProAxsis' ability to monitor bacterial infections in real time in patients suffering from lung diseases,' chief executive Ian Postlethwaite said.

'NEATstik has the potential to provide clinicians with a test identifying those at risk of further exacerbations providing more targeted care.'

'We believe that ProAxsis has the potential to become a significant player in the growing point-of-care respiratory testing market.'

At 9:04am: [LON:NSCI] Netscientific Plc share price was +3.25p at 11.75p

Story provided by